Again, information and lower execution costs are where Insto's have an advantage over retail. In that former vein, just to let you know MACI got a feature in MSB's Bell Potter presentation when talking about its own degenerative disc disease treatment (I hate that they call it back pain - too unspecific). I believe the potential for chondrocytes in DDD well under-estimated, despite the known role of endplates degeneration (and tenocytes in the collagenous annulus fibrous):
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029037/
ACI has taken a back seat to CelGro and ATI - its only a small company with limited resources - but perhaps some future venture with Vericel not off the table. Orthocell actually compared themselves to Vericel quite a few years back:
Ann: Investor Presentation, page-46
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $77.45M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 37.0¢ | 37.0¢ | $34.15K | 92.31K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5000 | 37.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.0¢ | 20208 | 2 |
View Market Depth
| Last trade - 10.07am 10/07/2024 (20 minute delay) ? |
| OCC (ASX) Chart |